Tango Therapeutics reported net income of -$55.34M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 6.79M | 5.72M | 5.76M | 5.77M | 6.92M | 6.41M | 5.77M | 14.60M | 10.73M | 5.43M | 6.47M | 19.88M | 11.61M | 4.12M | 5.39M | 3.18M | 53.81M | ||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 21.92M | 21.63M | 24.33M | 23.74M | 28.74M | 29.09M | 28.04M | 28.67M | 27.15M | 31.34M | 38.06M | 38.65M | 33.26M | 33.94M | 36.44M | 32.81M | 30.82M | 32.10M | 33.53M | 37.20M | |||||
| Selling, General & AdministrativeSG&A | 4.43M | 6.07M | 6.81M | 7.23M | 8.10M | 7.89M | 8.01M | 9.17M | 9.21M | 9.11M | 10.66M | 10.77M | 11.22M | 11.09M | 11.48M | 11.34M | 8.92M | 9.76M | 15.23M | 22.59M | |||||
| Other Operating ExpensesOther Opex | |||||||||||||||||||||||||
| Operating ExpensesOpex | 26.36M | 27.70M | 31.14M | 30.97M | 36.84M | 36.98M | 36.05M | 37.84M | 36.36M | 40.44M | 48.73M | 49.43M | 44.48M | 45.03M | 47.92M | 44.15M | 39.74M | 41.86M | 48.77M | 59.78M | |||||
| Operating IncomeOp. Inc | -19.57M | -21.98M | -25.38M | -25.20M | -29.92M | -30.57M | -30.29M | -23.25M | -25.63M | -35.01M | -42.26M | -29.55M | -32.88M | -40.91M | -42.53M | -40.97M | 14.07M | -41.86M | -48.77M | -59.78M | |||||
| EBIT | -19.57M | -21.98M | -25.38M | -25.20M | -29.92M | -30.57M | -30.29M | -23.25M | -25.63M | -35.01M | -42.26M | -29.55M | -32.88M | -40.91M | -42.53M | -40.97M | 14.07M | -41.86M | -48.77M | -59.78M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | -0.01M | -0.76M | -2.65M | -0.94M | -0.51M | 1.15M | 1.50M | 0.68M | 0.84M | 0.87M | -0.44M | ||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | |||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.05M | -0.08M | -0.05M | 0.05M | 0.52M | 0.97M | 1.22M | 1.15M | 1.51M | 2.06M | 2.18M | 2.00M | 1.96M | 1.48M | 1.07M | 0.91M | 0.70M | 3.44M | 1.08M | 0.72M | |||||
| Non Operating IncomeNon Op. Inc. | 0.04M | 0.12M | 0.17M | 0.35M | 0.87M | 1.56M | 2.28M | 2.60M | 3.39M | 4.30M | 4.38M | 4.07M | 3.77M | 3.29M | 2.69M | 2.15M | 1.80M | 3.06M | 3.26M | 4.45M | |||||
| Net income details | |||||||||||||||||||||||||
| EBT | -19.53M | -21.87M | -25.21M | -24.86M | -29.05M | -29.01M | -28.01M | -20.65M | -22.24M | -30.72M | -37.87M | -25.49M | -29.11M | -37.62M | -39.84M | -38.82M | 15.87M | -38.80M | -45.51M | -55.34M | |||||
| Tax ProvisionsTaxes | 0.06M | 0.18M | 0.00M | 0.10M | 0.10M | 0.02M | 0.03M | 0.04M | 0.07M | 0.05M | 0.01M | 0.03M | 0.04M | -0.01M | -21.43M | 0.00M | 0.00M | ||||||||
| Profit After TaxPAT | -19.60M | -22.80M | -25.21M | -24.86M | -29.56M | -27.91M | -28.01M | -20.71M | -22.26M | -30.76M | -37.91M | -25.55M | -29.17M | -37.67M | -39.88M | -38.85M | 15.88M | -38.86M | -45.51M | -55.34M | |||||
| Income from Continuing OperationsIncome (Continuing) | -19.59M | -22.05M | -25.21M | -24.86M | -29.05M | -29.11M | -28.01M | -20.75M | -22.26M | -30.75M | -37.91M | -25.55M | -29.17M | -37.63M | -39.88M | -38.85M | 15.88M | -17.37M | -45.51M | -55.34M | |||||
| Consolidated Net IncomeConsol Net Inc. | -19.59M | -22.05M | -25.21M | -24.86M | -29.05M | -29.11M | -28.01M | -20.75M | -22.26M | -30.75M | -37.91M | -25.55M | -29.17M | -37.63M | -39.88M | -38.85M | 15.88M | -17.37M | -45.51M | -55.34M | |||||
| Income towards Parent CompanyParent Net Inc | -19.59M | -22.05M | -25.21M | -24.86M | -29.05M | -29.11M | -28.01M | -20.75M | -22.26M | -30.75M | -37.91M | -25.55M | -29.17M | -37.63M | -39.88M | -38.85M | 15.88M | -17.37M | -45.51M | -55.34M | |||||
| Net Income towards Common StockholdersNet Income | -19.59M | -22.05M | -25.21M | -24.86M | -29.05M | -29.11M | -28.01M | -20.75M | -22.26M | -30.75M | -37.91M | -25.55M | -29.17M | -37.63M | -39.88M | -38.85M | 15.88M | -17.37M | -45.51M | -55.34M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.28 | -0.36 | -0.29 | -0.28 | -0.33 | -0.33 | -0.32 | -0.23 | -0.23 | -0.33 | -0.35 | -0.24 | -0.27 | -0.34 | -0.36 | -0.35 | 0.14 | -0.15 | -0.32 | -0.37 | |||||
| EPS (Diluted) | -0.28 | -0.36 | -0.29 | -0.28 | -0.33 | -0.33 | -0.32 | -0.23 | -0.23 | -0.33 | -0.35 | -0.24 | -0.27 | -0.34 | -0.36 | -0.35 | 0.13 | -0.15 | -0.32 | -0.37 | |||||
| Shares Outstanding | 70.16M | 62.11M | 87.67M | 87.84M | 87.89M | 87.82M | 88.19M | 88.35M | 97.03M | 94.57M | 108.17M | 108.31M | 108.51M | 109.23M | 110.30M | 110.54M | 110.97M | 116.17M | 143.58M | 149.88M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 70.16M | 62.11M | 87.67M | 87.84M | 87.89M | 87.82M | 88.19M | 88.35M | 97.03M | 94.57M | 108.17M | 108.31M | 108.51M | 109.23M | 110.30M | 110.54M | 117.78M | 116.17M | 143.58M | 149.88M | |||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 70.16M | 62.11M | 87.71M | 88.00M | 88.07M | 88.18M | 88.21M | 88.46M | 101.85M | 102.20M | 106.73M | 107.04M | 107.41M | 107.73M | 108.11M | 110.87M | 111.57M | 135.94M | 144.16M | 168.38M | |||||
| EBITDA | -19.57M | -21.98M | -25.38M | -25.20M | -29.92M | -30.57M | -30.29M | -23.25M | -25.63M | -35.01M | -42.26M | -29.55M | -32.88M | -40.91M | -42.53M | -40.97M | 14.07M | -41.86M | -48.77M | -59.78M | |||||
| Tax Rate | -0.32% | -0.85% | -0.01% | -0.33% | -0.48% | -0.10% | -0.11% | -0.11% | -0.26% | -0.19% | -0.02% | -0.09% | -0.09% | -0.06% | 55.24% | 0.00% | 0.00% |